Biomarker & Intervention Discovery
Systemic Lupus Erythematosus (SLE)
Pharmacologically actionable gene targets, therapeutic agents ranked by evidence tier, and active clinical trials.
NIH funding$148MFY2025 · RCDC estimate
Funding levelWell-Funded
Spontaneous remissionSpontaneous drug-free remission: 2-10% in some cohorts over 5 years; disease-free survival in 15-20% at 20 years…
Best-intervention remissionTriple therapy (hydroxychloroquine + MMF + belimumab): 43% complete renal response at 52 weeks (BLISS-LN); voclosporin…
Gap sizeLarge — hydroxychloroquine is dramatically underprescribed; newer biologics (belimumab, anifrolumab) reach very few…
Primary barrieraccess/practice
Full remission profile →
Remission & chronicity
Spontaneous remission
Spontaneous drug-free remission: 2-10% in some cohorts over 5 years; disease-free survival in 15-20% at 20 years; renal lupus (LN) progression to ESRD in 10-20% within 20 years on standard care
Best-intervention remission
Triple therapy (hydroxychloroquine + MMF + belimumab): 43% complete renal response at 52 weeks (BLISS-LN); voclosporin + MMF: 40.8% complete renal response; anifrolumab (anti-IFNAR): 47.8% BICLA response in active SLE (TULIP-2); aggressive treat-to-target achieves low disease activity in 60-70%
Gap size
Large — hydroxychloroquine is dramatically underprescribed; newer biologics (belimumab, anifrolumab) reach very few eligible patients
Primary barrier
access/practice
Hydroxychloroquine (the safest, most evidence-based lupus drug) was underprescribed even before COVID-19 controversy; biologics (belimumab, anifrolumab) approved since 2011 and 2021 respectively but used in <15% of eligible patients; racial disparities profound (Black/Hispanic patients have 2-3x higher disease severity and mortality but lower biologic access)
Biomarker Targets & Therapeutic Agents
Gene targets queried against DGIdb, Open Targets, ChEMBL, PubMed, and Europe PMC.
Agents ranked: ● Clinical >
● Mechanistic >
● Correlative.
Pipeline results not yet available. Run: python -m biomarker_pipeline.run_for_diseases --skip-llm
Clinical Trials
Recruiting and recently completed trials from ClinicalTrials.gov.
Data retrieved 2026-07-06.
No recent clinical trials found on ClinicalTrials.gov for this condition.
Agents Found By Disease-Level Search
Searched directly from “Systemic Lupus Erythematosus (SLE)” via ClinicalTrials.gov interventions and Open Targets'
disease→drug data — independent of the 0-gene target panel above.
This surfaces agents whose mechanism doesn't route through a curated gene (combination
therapies, standard-of-care drugs, targets outside the panel).
Not yet run. python -m biomarker_pipeline.run_disease_agent_discovery --disease "..."